Ann Childress, MD
Center for Psychiatry And Behavioral Medicine Inc.
8
7
6
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Matt Brams, MD
Cingulate
Shared therapeutic areas:
Worked with same sponsors:
Carolyn R Sikes, PhD
Neos Therapeutics, Inc
Shared therapeutic areas:
Worked with same sponsors:
Scott Kollins, MD
Department of Psychiatry & Behavioral Sciences, Duke University, Durham, NC
Shared therapeutic areas:
Worked with same sponsors:
Patrick J. McGrath, PhD.
IWK Health Centre
Shared therapeutic areas:
Daniel S Pine, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Ru-Lan Hsieh, MD
Shin Kong Wu Ho-Su Memorial Hospital
Shared therapeutic areas:
Renana Eitan, MD
Hadassah Medical Organization
Shared therapeutic areas:
Sabine Wilhelm, PhD
Massachusetts General Hospital
Shared therapeutic areas:
Theresa Winhusen, Ph.D.
University of Cincinnati
Shared therapeutic areas:
Karen Sepucha, PhD
Massachusetts General Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
All 8 trials loaded